Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:EMH CVE:HEM NASDAQ:ONC NASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsHEMHemostemixC$0.14+3.7%C$0.12C$0.04▼C$0.43C$20.40M0.2408,721 shs272,977 shsONCBeOne Medicines$251.51-1.6%$247.35$146.21▼$287.88$27.57B0.28433,913 shs12,239 shsPMNPromis Neurosciences$0.39-0.3%$0.50$0.38▼$2.37$12.78M-0.182,325 shs10,347 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%HEMHemostemix+3.70%-6.67%+16.67%+55.56%+211.11%ONCBeOne Medicines+4.59%+4.65%-3.07%+22.74%+25,568,999,900.00%PMNPromis Neurosciences-3.02%-12.48%-22.36%-29.10%-82.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines3.3767 of 5 stars4.50.00.00.02.41.70.6PMNPromis Neurosciences3.3816 of 5 stars3.55.00.00.00.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health Therapeutics 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$320.6727.50% UpsidePMNPromis Neurosciences 3.00Buy$4.501,050.90% UpsideCurrent Analyst Ratings BreakdownLatest HEM, ONC, EMH, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/12/2025PMNPromis NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64HEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/AONCBeOne Medicines$3.81B7.23N/AN/A$34.10 per share7.38PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/AONCBeOne Medicines-$644.79M-$3.72N/A354.24N/A-9.40%-7.55%-4.42%N/APMNPromis Neurosciences$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)Latest HEM, ONC, EMH, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PMNPromis Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61HEMHemostemix-55.070.040.48ONCBeOne Medicines0.051.961.71PMNPromis NeurosciencesN/A3.363.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/AHEMHemostemixN/AONCBeOne Medicines48.55%PMNPromis Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/AHEMHemostemix10.43%ONCBeOne Medicines6.62%PMNPromis Neurosciences6.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableHEMHemostemixN/A145.73 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/APMNPromis Neurosciences532.69 million30.69 millionNot OptionableHEM, ONC, EMH, and PMN HeadlinesRecent News About These CompaniesProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 17, 2025 | globenewswire.comProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's DiseaseMay 13, 2025 | nasdaq.comProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | BenzingaMay 13, 2025 | benzinga.comProMIS Neurosciences Announces First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last yearMarch 31, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceMarch 24, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingMarch 13, 2025 | globenewswire.comProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceMarch 11, 2025 | globenewswire.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s DiseaseFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trialFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's DiseaseFebruary 25, 2025 | globenewswire.comProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating OfficerFebruary 20, 2025 | marketwatch.comProMIS Neurosciences seperates from COO Malenfant, terminates COO positionFebruary 20, 2025 | markets.businessinsider.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 SharesFebruary 13, 2025 | insidertrades.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comFProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comFProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26January 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?These 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsBy Chris Markoch | July 1, 2025View 3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyHEM, ONC, EMH, and PMN Company DescriptionsEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Hemostemix CVE:HEMC$0.14 +0.01 (+3.70%) As of 07/9/2025 03:34 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.BeOne Medicines NASDAQ:ONC$251.51 -4.18 (-1.63%) As of 09:55 AM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Promis Neurosciences NASDAQ:PMN$0.39 0.00 (-0.28%) As of 10:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will Oracle's Cloud and AI Deals Propel It to New Highs? Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
